{
  "abstract": "The modified Rankin Scale (mRS), which measures the degree of disability or dependence in daily activities after a stroke, serves as the primary endpoint in most acute stroke clinical trials. Its simplicity, strong validity for stroke outcomes, and reliable inter-rater agreement—particularly when a structured assessment is used—have contributed to its widespread adoption. Developed in 1957 by John Rankin (1923–1981), the original 5-grade scale assessed functional recovery in patients with stroke, ranging from grade 1 (no significant disability) to grade 5 (severe disability).1 The scale was modified to its current 7-grade form by Warlow and colleagues for use in the United Kingdom Transient Ischemic Attack (UK-TIA) trial in the 1980s, with the addition of the extreme grades of 0 for no symptoms at all and 6 for death.2",
  "authors": [
    {
      "affiliations": [
        "Semmes Murphey Neurologic and Spine Institute, Memphis, Tennessee, USA",
        "Neurology and Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA"
      ],
      "name": "Violiza Inoa"
    },
    {
      "affiliations": [
        "Semmes Murphey Neurologic and Spine Institute, Memphis, Tennessee, USA",
        "Neurology and Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA"
      ],
      "name": "Nitin Goyal"
    },
    {
      "affiliations": [
        "Neurology, UCLA, Los Angeles, California, USA",
        "Comprehensive Stroke Center and Neurology, David Geffen School of Medicine, Los Angeles, California, USA"
      ],
      "name": "Jeffrey L Saver"
    },
    {
      "affiliations": [
        "Diagnostic Imaging, University of Calgary, Calgary, Alberta, Canada"
      ],
      "name": "Mayank Goyal"
    }
  ],
  "title": "Is the modified Rankin Scale still the right endpoint for neurointerventional trials?",
  "uid": "6867a431-0a2d-5cfa-86d4-1ff3b694cb48"
}